192 related articles for article (PubMed ID: 35476143)
1. [Galcanezumab for episodic and chronic cluster headache].
Pohl H; Holle-Lee D; Broicher SD; Schwerdtner I; Gantenbein AR; Gaul C
Schmerz; 2023 Jun; 37(3):168-174. PubMed ID: 35476143
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
Dodick DW; Goadsby PJ; Lucas C; Jensen R; Bardos JN; Martinez JM; Zhou C; Aurora SK; Yang JY; Conley RR; Oakes T
Cephalalgia; 2020 Aug; 40(9):935-948. PubMed ID: 32050782
[TBL] [Abstract][Full Text] [Related]
3. Drug profile: galcanezumab for prevention of cluster headache.
Mudugal D; Monteith TS
Expert Rev Neurother; 2021 Feb; 21(2):145-155. PubMed ID: 33206562
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
Membrilla JA; Torres-Ferrus M; Alpuente A; Caronna E; Pozo-Rosich P
Headache; 2022 Nov; 62(10):1395-1405. PubMed ID: 36321947
[TBL] [Abstract][Full Text] [Related]
5. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
7. Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.
Scott LJ
Drugs; 2020 Jun; 80(9):893-904. PubMed ID: 32504377
[TBL] [Abstract][Full Text] [Related]
8. Galcanezumab for the prevention of cluster headache.
Giani L; Proietti Cecchini A; Leone M
Expert Opin Biol Ther; 2020 Oct; 20(10):1133-1142. PubMed ID: 32702245
[TBL] [Abstract][Full Text] [Related]
9. Trial of Galcanezumab in Prevention of Episodic Cluster Headache.
Goadsby PJ; Dodick DW; Leone M; Bardos JN; Oakes TM; Millen BA; Zhou C; Dowsett SA; Aurora SK; Ahn AH; Yang JY; Conley RR; Martinez JM
N Engl J Med; 2019 Jul; 381(2):132-141. PubMed ID: 31291515
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache.
Kudrow D; Andrews JS; Rettiganti M; Oakes T; Bardos J; Gaul C; Riesenberg R; Wenzel R; Kuruppu D; Martinez J
Headache; 2020 Nov; 60(10):2254-2264. PubMed ID: 33179263
[TBL] [Abstract][Full Text] [Related]
12. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
Ossipov MH; Raffa RB; Pergolizzi JV
Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
[TBL] [Abstract][Full Text] [Related]
13. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures.
Schwedt TJ; Kuruppu DK; Dong Y; Standley K; Yunes-Medina L; Pearlman E
J Headache Pain; 2021 Mar; 22(1):15. PubMed ID: 33765912
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
Lamas Pérez R; Millán-Vázquez M; González-Oria C
Cephalalgia; 2024 Mar; 44(3):3331024231226181. PubMed ID: 38501892
[TBL] [Abstract][Full Text] [Related]
15. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
17. CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache.
Chen ST; Wu JW
Curr Pain Headache Rep; 2022 Sep; 26(9):667-675. PubMed ID: 35881279
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache.
Mo H; Kim BK; Moon HS; Cho SJ
J Headache Pain; 2022 Oct; 23(1):132. PubMed ID: 36209047
[TBL] [Abstract][Full Text] [Related]
19. CGRP pathway monoclonal antibodies for cluster headache.
Chan C; Goadsby PJ
Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
[TBL] [Abstract][Full Text] [Related]
20. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
